These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30401981)

  • 1. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
    Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
    Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade.
    Tanaka I; Osada H; Fujii M; Fukatsu A; Hida T; Horio Y; Kondo Y; Sato A; Hasegawa Y; Tsujimura T; Sekido Y
    Oncogene; 2015 Jan; 34(1):73-83. PubMed ID: 24336325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
    Kim M; Kim T; Johnson RL; Lim DS
    Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
    Cunningham R; Jia S; Purohit K; Salem O; Hui NS; Lin Y; Carragher NO; Hansen CG
    Clin Transl Med; 2023 Feb; 13(2):e1190. PubMed ID: 36740402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways.
    Santinon G; Pocaterra A; Dupont S
    Trends Cell Biol; 2016 Apr; 26(4):289-299. PubMed ID: 26750334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.
    Mizuno T; Murakami H; Fujii M; Ishiguro F; Tanaka I; Kondo Y; Akatsuka S; Toyokuni S; Yokoi K; Osada H; Sekido Y
    Oncogene; 2012 Dec; 31(49):5117-22. PubMed ID: 22286761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.
    Sekido Y
    Pathol Int; 2011 Jun; 61(6):331-44. PubMed ID: 21615608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
    Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
    Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
    Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
    J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations.
    Rehrauer H; Wu L; Blum W; Pecze L; Henzi T; Serre-Beinier V; Aquino C; Vrugt B; de Perrot M; Schwaller B; Felley-Bosco E
    Oncogene; 2018 May; 37(20):2645-2659. PubMed ID: 29507420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner.
    Shanzer M; Ricardo-Lax I; Keshet R; Reuven N; Shaul Y
    Oncogene; 2015 Aug; 34(32):4190-8. PubMed ID: 25362852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
    Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
    J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors.
    Hagenbeek TJ; Webster JD; Kljavin NM; Chang MT; Pham T; Lee HJ; Klijn C; Cai AG; Totpal K; Ravishankar B; Yang N; Lee DH; Walsh KB; Hatzivassiliou G; de la Cruz CC; Gould SE; Wu X; Lee WP; Yang S; Zhang Z; Gu Q; Ji Q; Jackson EL; Lim DS; Dey A
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hippo pathway transcription factors YAP and TAZ play HPV-type dependent roles in cervical cancer.
    Patterson MR; Cogan JA; Cassidy R; Theobald DA; Wang M; Scarth JA; Anene CA; Whitehouse A; Morgan EL; Macdonald A
    Nat Commun; 2024 Jul; 15(1):5809. PubMed ID: 38987584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer.
    Vahid S; Thaper D; Gibson KF; Bishop JL; Zoubeidi A
    Sci Rep; 2016 Aug; 6():31842. PubMed ID: 27555231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.